Centre caps trade margins on non-scheduled cancer drugs at 30% of MRP; prices change only after NPPA notifies

This note is NP NOW. The stamp is verified. It was rechecked at 1:05 pm IST on 10 October 2026 and posted at 1:05 pm IST.

On 8 October 2026 the Centre approved a cap on trade margins for non-scheduled anti-cancer drugs. The cap is 30 percent of MRP. The record for that approval is a Press Information Bureau release from the Department of Pharmaceuticals, PRID 2321092. The department also posted the decision on X. The Hindu reports the same cap: trade margins on non-scheduled cancer drugs, at 30 percent of MRP.

The approval is the decision. It is not, by itself, a new price. Prices change only after NPPA notifies, and only for drugs on the DGHS list. That sequence is the step in NPPA minutes, as reported by News18 and ETV Bharat. A drug that is not on the DGHS list is outside the notification step this note describes. An NPPA notification that has not been issued is not a changed price.

Read the two parts separately, because they answer different questions. The first is what was approved. On 8 October, trade margins on non-scheduled anti-cancer drugs were capped at 30 percent of MRP. That is the PIB release, PRID 2321092, and it is what the department posted. The second is when a price moves. It moves after NPPA notifies, and only for a drug that is on the DGHS list. News18 and ETV Bharat are the outlets cited for that step, from the NPPA minutes. The Hindu is cited for the cap itself.

Five sources sit under this article. They are the PIB release, the Department of Pharmaceuticals post on X, News18, ETV Bharat and The Hindu. No sixth outlet is added. The 30 percent figure in this note is the cap on the trade margin, as a share of MRP. It is not a discount written out as money saved, and it is not a count of how many drugs sit on a list.

This note stops at that cap and that sequence. It does not give a savings figure. It does not give a count of drugs. It does not give a date for the DGHS list beyond the order already stated: the list, then the NPPA notification. The words "non-scheduled anti-cancer drugs" are the release's category. This note does not add a definition of the schedule, and it does not add a worked example of a margin.

Rechecked at 1:05 pm IST on 10 October, the position is unchanged from the 8 October approval. The cap is 30 percent of MRP, on the trade margin, for non-scheduled anti-cancer drugs. Prices change when NPPA notifies, and only for the drugs on the DGHS list. Until that notification, this note does not describe a price as already changed.

The cover is an NP typographic graphic. No photograph is used. No person is shown.